FDA approves CRISPR's CASGEVY for transfusion-dependent beta thalassemia in patients 12+

CRISPR Therapeutics AG

U.S. FDA approved CASGEVY (exagamglogene autotemcel) on Jan 16, 2024 for transfusion-dependent beta thalassemia in patients 12 years and older.
CASGEVY is a CRISPR/Cas9 gene-edited cell therapy developed by CRISPR Therapeutics.
The approval expands treatment options for patients with transfusion-dependent beta thalassemia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.